高聚金葡素联合参芪片对乳腺癌CEF新辅助化疗的减毒作用

[目的]评价高聚金葡素联合参芪片对乳腺癌CEF新辅助化疗的减毒作用.[方法]细针穿刺活检证实为乳腺癌患者86例,随机分为治疗组和对照组各43例,治疗组行CEF方案化疗,期间给予高聚金葡素联合参芪片辅助治疗.对照组给予利血生、鲨肝醇治疗.各行CEF方案化疗2周期.观察化疗后消化道反应、体力状况、心电图的变化;观察化疗前及化疗后第14、21、24天白细胞、血小板计数及血红蛋白含量的变化.测定化疗前及化疗后第12、24天外周血CD3、CD4、CD8、CD4/CD8.[结果]化疗后,治疗组每次白细胞、血小板平均计数、血红蛋白含量较对照组高(P＜0.05),外周血CD3、CD4细胞百分比、CD4/CD8比值较化疗前均有升高,且明显高于对照组(P＜0.05),疲乏感病例数少,在第2周期化疗后,发生心动过速、早搏或心电图ST、T改变的病例数少于对照组(P＜0.05).治疗组顺利完成化疗,按计划行手术治疗.对照组完成化疗后,12例按计划行手术治疗,31例继续对症毒副反应治疗,治疗后第10～15天行手术治疗.[结论]采用高聚金葡素联合参芪片辅助治疗对乳腺癌CEF新辅助化疗具有明显的保护骨髓、心肌,增强体能及免疫功能的作用.

Effect of Highly Agglutinative Staphglococc Combined with Shenqi Tablets on Reducing The Toxicity of Neoadjuvant Chemotherapy with CEF Regimen for Breast Cancer

To estimate the effects of Highly Agglutinative Staphglococcin(HAS) combined with Shenqi tablets on reducing the toxicity of CEF(CTX, EPI, 5-Fu) neoadjuvant chemotherapy with CEF (CTX, EPI, 5-Fu) regimen in patients with breast cancer. Eighty-six cases with breast cancer histologically proved from fine needle aspiration were divided into treatment group and control group randomly with 43 patients in each group. Treatment group received HAS combined with Chenqi tablets, and control group received Leucosonura combined with Batilol tablets during 2 cycles of neoadjuvant chemotherapy with CEF regimen. Toxicity of digestive tract , performance status and EKG change were observed after neoadjuvant chemotherapy. White blood cell, hemoglobine, platelet were measured before and at the 14th, 21th, 24th day after neoadjuvant chemotherapy. The value of CD3, CD4, CD8, CD4/CD8 were determined before and at the 12th, 24th day after neoadjuvant chemotherapy. After each cycle of neoadjuvant chemotherapy, white blood cell, hemoglobine, platelet of the treatment group were much higher than those of control group(P<0.05). The value of CD3, CD4, CD4/CD8 in treatment group were much higher than that in control group(P<0.05). Patients with fatigue were fewer in treatment group than control group. After the 2nd cycle of neoadjuvant chemotherapy, fewer arrhythma, abnormality of ST segment or T wave on EKG took place in treatment group than those in control group(P<0.05). In treatment group, after completed neo-adjuvant chemotherapy all underwent planned operation in time. Whereas only 12 cases in control group underwent operation as planning. Operations of the remainder 31 cases were delayed for 10~15 days due to obvious side-effects. [Conclusion] HAS combined with Shenqi tablets could reduce the extent of bone marrow inhibition, cardiac toxicity and fatigue, and improve immunity during neoadjuvant chemotherapy with CEF regimen in patients with breast cancer and make the operation as planning in time.